CA3172328A1 - Nerve cell degeneration inhibitor - Google Patents
Nerve cell degeneration inhibitor Download PDFInfo
- Publication number
- CA3172328A1 CA3172328A1 CA3172328A CA3172328A CA3172328A1 CA 3172328 A1 CA3172328 A1 CA 3172328A1 CA 3172328 A CA3172328 A CA 3172328A CA 3172328 A CA3172328 A CA 3172328A CA 3172328 A1 CA3172328 A1 CA 3172328A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- met
- kyl
- wherei
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/42—One nitrogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020-058414 | 2020-03-27 | ||
| JP2020058414 | 2020-03-27 | ||
| PCT/JP2021/014251 WO2021193982A1 (ja) | 2020-03-27 | 2021-03-26 | 神経細胞変性阻害剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3172328A1 true CA3172328A1 (en) | 2021-09-30 |
Family
ID=77892307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3172328A Pending CA3172328A1 (en) | 2020-03-27 | 2021-03-26 | Nerve cell degeneration inhibitor |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230120205A1 (https=) |
| EP (1) | EP4129293A4 (https=) |
| JP (1) | JP7840054B2 (https=) |
| CN (1) | CN115335058B (https=) |
| CA (1) | CA3172328A1 (https=) |
| WO (1) | WO2021193982A1 (https=) |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050070524A1 (en) * | 2003-06-06 | 2005-03-31 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders |
| ZA200709038B (en) * | 2005-04-13 | 2009-01-28 | Neuraxon Inc | Substituted indole compounds having nos inhibitory activity |
| JP5693951B2 (ja) * | 2007-04-24 | 2015-04-01 | アストラゼネカ エービー | プロテインキナーゼの阻害剤 |
| EP2137164B1 (en) * | 2007-04-24 | 2015-08-26 | AstraZeneca AB | Inhibitors of protein kinases |
| EP2137163B1 (en) * | 2007-04-24 | 2015-03-18 | AstraZeneca AB | Inhibitors of protein kinases |
| ES2579949T3 (es) * | 2010-02-05 | 2016-08-17 | Heptares Therapeutics Limited | Derivados de 1,2,4-triazin-4-amina |
| US20130079345A1 (en) * | 2010-03-22 | 2013-03-28 | Bayer Intellectual Property Gmbh | Pharmaceutically active disubstituted triazine derivatives |
| TWI555737B (zh) * | 2011-05-24 | 2016-11-01 | 拜耳知識產權公司 | 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺 |
| EP2561867A1 (en) * | 2011-08-22 | 2013-02-27 | Lead Discovery Center GmbH | CDK9 inhibitors in the treatment of midline carcinoma |
| JP6473077B2 (ja) | 2013-03-21 | 2019-02-20 | 国立大学法人京都大学 | 神経分化誘導用の多能性幹細胞 |
| CN107530430A (zh) * | 2015-01-13 | 2018-01-02 | 国立大学法人京都大学 | 用于预防和/或治疗肌萎缩性侧索硬化症的药剂 |
| CN105085427B (zh) * | 2015-08-21 | 2018-06-05 | 中国科学院广州生物医药与健康研究院 | 一类苯并[d]异恶唑类化合物及其应用 |
| GB201605126D0 (en) * | 2016-03-24 | 2016-05-11 | Univ Nottingham | Inhibitors and their uses |
| CN107304189A (zh) * | 2016-04-18 | 2017-10-31 | 北京大学 | 一种三嗪化合物及其制备方法和应用 |
| JP6959632B2 (ja) | 2017-05-15 | 2021-11-02 | 学校法人近畿大学 | 筋萎縮性側索硬化症又は前頭側頭型認知症の予防又は治療剤 |
| CN110582491B (zh) * | 2017-06-30 | 2023-09-29 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
| AU2018342105B2 (en) * | 2017-09-26 | 2023-11-16 | University Of Florida Research Foundation, Incorporated | Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders |
| EP4234553A3 (en) * | 2018-05-09 | 2023-09-06 | Design Therapeutics, Inc. | Methods and compounds for the treatment of genetic disease |
| JP7135692B2 (ja) | 2018-10-05 | 2022-09-13 | ニプロ株式会社 | 排液システム |
-
2021
- 2021-03-26 CA CA3172328A patent/CA3172328A1/en active Pending
- 2021-03-26 CN CN202180024013.0A patent/CN115335058B/zh active Active
- 2021-03-26 EP EP21774856.5A patent/EP4129293A4/en not_active Withdrawn
- 2021-03-26 WO PCT/JP2021/014251 patent/WO2021193982A1/ja not_active Ceased
- 2021-03-26 US US17/906,127 patent/US20230120205A1/en not_active Abandoned
- 2021-03-26 JP JP2022510782A patent/JP7840054B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20230120205A1 (en) | 2023-04-20 |
| EP4129293A4 (en) | 2024-04-03 |
| CN115335058A (zh) | 2022-11-11 |
| EP4129293A1 (en) | 2023-02-08 |
| JPWO2021193982A1 (https=) | 2021-09-30 |
| JP7840054B2 (ja) | 2026-04-03 |
| CN115335058B (zh) | 2024-12-06 |
| WO2021193982A1 (ja) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12577256B2 (en) | Aryl receptor modulators and methods of making and using the same | |
| AU2021229240B2 (en) | Compositions comprising 2-((1-(2(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia | |
| EP3030549B1 (en) | Pyridazinone compounds and uses thereof | |
| RU2654910C2 (ru) | Производные бензилиденгуанидина и их терапевтическое применение для лечения заболеваний, связанных с неправильным сворачиванием белков | |
| RS54651B1 (sr) | Inhibitori janus kinaza za lečenje suvog oka i drugih očnih obolenja | |
| WO2010101649A2 (en) | Sigma 1 receptor inhibition as a novel therapeutical approach against hepatitis c virus infection | |
| WO2004067008A1 (ja) | 受容体作動薬 | |
| EP3265443B1 (en) | Pyrrolidine carboxamido derivatives and methods for preparing and using the same | |
| EP2651403A2 (en) | Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases | |
| WO2021017384A1 (zh) | 二氢吡咯并嘧啶类选择性jak2抑制剂 | |
| US20200268687A1 (en) | Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemia | |
| AU2017380583A1 (en) | Triazinetrione derivatives and their use as modulators of neurotrophin receptor and receptor tyrosine kinases | |
| US8987321B2 (en) | Lisofylline analogs and methods for use | |
| CA3172328A1 (en) | Nerve cell degeneration inhibitor | |
| HK40082876A (en) | Nerve cell degeneration inhibitor | |
| KR100602976B1 (ko) | 심리학적 장애의 치료를 위한 게피론의 생활성 대사물질의용도 | |
| CA2907921C (en) | Inhibition of il-2 production | |
| JP7618237B2 (ja) | 運動神経細胞変性阻害剤 | |
| WO2023067388A1 (en) | Uses of cftr modulator and/or pde4 inhibitor compounds | |
| HK40073574B (zh) | 以稠合嘧啶化合物为有效成分的治疗剂 | |
| HK40073574A (en) | Therapeutic agent containing fused pyrimidine compound as active ingredient | |
| CN121318838A (zh) | 一种喹啉酮类衍生物及其制备方法和应用 | |
| CN114828856A (zh) | 以稠合嘧啶化合物为有效成分的治疗剂 | |
| HK40000275B (en) | Compounds having melatonin receptor affinity as prophylactic or therapeutic agent for delirium | |
| WO2017151006A1 (ru) | Фармацевтическая композиция для лечения функциональных психических расстройств |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220919 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240917 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250110 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250212 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250221 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250221 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250221 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250617 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250617 |